Full Breakdown
OpenEvidence Achieves $12 Billion Valuation in Latest Funding Round
1/22/2026, 6:40:31 AM
Rapid Growth and Funding Success
OpenEvidence, an artificial intelligence startup based in Miami, Florida, has recently secured a $250 million funding round, doubling its valuation to $12 billion. The financing was co-led by Thrive Capital and DST Global, contributing to a total of nearly $700 million raised by the company since its inception in 2022. OpenEvidence, often referred to as "ChatGPT for doctors," specializes in providing AI-driven chatbots trained on data from reputable medical journals, distinguishing itself from competitors by focusing on high-quality, specialized medical content.
The company was founded by Daniel Nadler, a billionaire entrepreneur known for his previous venture, Kensho Technologies, and Zachary Ziegler, a former PhD student at Harvard. OpenEvidence's rapid valuation increase reflects growing investor interest in healthcare-focused AI solutions that demonstrate real-world application and adoption.
Strategic Partnerships and Market Position
OpenEvidence has established partnerships with notable organizations, including the New England Journal of Medicine and the American Medical Association, to enhance the accuracy and trustworthiness of its AI models. Nadler emphasized that the company’s approach to training its AI on trusted medical sources, rather than general internet data, addresses significant concerns regarding the reliability of AI in healthcare.
The startup's business model relies on advertising for revenue, which Nadler claims positions it favorably against competitors like OpenAI, which recently announced plans to introduce ads on its platforms. OpenEvidence reported over $100 million in annualized revenue last year, primarily driven by organic growth, with 95% of new users coming from referrals by other doctors.
Industry Context and Future Outlook
The healthcare sector represents a substantial portion of the U.S. economy, accounting for nearly 20% of the gross domestic product. Nadler noted the potential for multiple winners in this space, as evidenced by the recent launches of HIPAA-compliant AI chatbots by industry giants like OpenAI and Anthropic. Despite the competitive landscape, Nadler believes OpenEvidence's extensive data and partnerships provide a significant advantage.
Looking ahead, OpenEvidence plans to utilize the new capital to invest in research and development and to scale its AI infrastructure. Nadler has expressed a desire to maintain the company's independence, contrasting with the acquisition strategies of larger AI firms. He indicated that OpenEvidence would consider an initial public offering (IPO) only after observing the public market performance of larger AI companies.
Criticism and Market Challenges
While OpenEvidence has garnered significant attention and investment, the broader AI industry faces challenges related to trust and accuracy in healthcare applications. Critics may point to the need for ongoing scrutiny of AI's role in medical decision-making and the potential risks associated with reliance on automated systems.
Verbatim Quotes
- “If you only squint from a distance, OpenEvidence is ‘ChatGPT’ for doctors. If you look closely, it’s a very different organism,” — Daniel Nadler, Founder
- “People realize there could be a lot of winners in the space.” — Daniel Nadler, Founder
- “Even if someone copied the playbook today, they'd still be far behind because it's not just the partnerships, it's the real-world usage data.” — Daniel Nadler, Founder
OpenEvidence's recent funding success and strategic positioning highlight its potential to become a significant player in the evolving landscape of AI in healthcare.
